Gilead shrugs off falling HCV drug sales in first quarter

3 May 2019

Boosted by a strong sales result from its HIV treatments and from novel cancer med Yescarta (axicabtagene ciloleucel), California’s Gilead Sciences (Nasdaq: GILD) beat analysts’ expectations to take in $5.3 billionsales in the first quarter of 2019.

Net income was $2 billion, which equates to an earnings per share (EPS) figure of $1.54. In the comparable period last year, the company took in $1.5 billion, or $1.17 per share.

The bulk of Gilead's revenues are from its domestic market, with sales in the first quarter topping $3.8 billion in the USA, compared with $882 million in Europe and $522 million in the rest of the world.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK